Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your genes predict a heart procedure complication?

NCT ID NCT05355532

Knowledge-focused Sponsor: Privolzhsky Research Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether certain genes are linked to a complication called 'no-reflow' that can happen during emergency artery-opening procedures for heart attacks. Researchers analyzed blood samples from 80 heart attack patients to find genetic markers. The goal is to better predict who is at risk for this complication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a genetic test to predict which heart attack patients are at risk of a complication called no-reflow during artery-opening procedures.
What could go wrong
This is a small, completed observational study, not a treatment trial. The findings are preliminary and may not lead to a usable test or change in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

80 people

The number who actually took part.

Started

Apr 2022

Finished

Mar 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with 1 type MI after emergency PCI

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. informed consent to participate in the study; 2. male or female 18 years of age or older; 3. type 1 ST-segment elevation MI (according to the criteria of the fourth universal definition of myocardial infarction and current clinical guidelines); 4. blood sampling in the operating room (immediately after PCI) and signing the informed consent; 5. for the "CMVO+" group: CMVO because of PCI (CMVO is registered according to the criteria from the European Society of Cardiology clinical guidelines); 6. for the "CMVO-" group: absence of CMVO after PCI; patient should compliance by sex and age (±5 years) with pair in the "CMVO+" group. Exclusion Criteria: 1. late admission (more than 48 hours from the onset of anginal pain) or early post-infarction angina pectoris; 2. not 1 type MI; 3. complications during PCI (dissection, perforation or acute intraoperative thrombosis of the IRA); 4. death during PCI, not due to the CMVO development; 5. concomitant terminal pathology (not associated with MI) with a life expectancy less than 1 month.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction No-Reflow Phenomenon ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction No-reflow phenomenon

Contacts and locations

Locations

  • Central Research Laboratory of the Privolzhsky Research Medical University

    Nizhny Novgorod, Nizhny Novgorod Oblast, 603104, Russia

  • City Clinical Hospital No. 13 of the Avtozavodsky District of Nizhny Novgorod

    Nizhny Novgorod, Nizhny Novgorod Oblast, 603018, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.